Normal Cerebrospinal Fluid Histamine and tele-Methylhistamine Levels in Hypersomnia Conditions
Normal Cerebrospinal Fluid Histamine and tele-Methylhistamine Levels in Hypersomnia Conditions
复制标题
DOI：
10.5665/sleep.2114
复制
发表时间：
2012-10-01
期刊：
影响因子：
5.6
通讯作者：
Robert, Philippe
中科院分区：
文献类型：
--
作者：
Dauvilliers, Yves;Delallee, Nathalie;Robert, Philippe
研究目的：通过脑脊液中组胺（HA）和远端甲基组胺（t-MHA）及其主要代谢物的水平评估脑组织胺能系统的活性，以及它们与大量嗜睡和神经系统疾病患者下丘脑泌素-1水平的关系。设计：建立了一种灵敏的液相色谱-电喷雾/串联质谱分析方法，用于同时定量CSF HA和t-MHA。环境：在法国蒙彼利埃睡眠障碍中心收集数据，使用放射免疫法测量脑脊液下丘脑分泌素-1水平。CSF HA和t-MHA在法国bioproject - biotech公司进行了测量。参与者：114名疑似中枢性嗜睡的无关联患者接受了一晚的多导睡眠描记仪，随后进行了多次睡眠潜伏期测试。通过临床和睡眠研究对睡眠障碍进行了诊断：发作性睡伴猝发性NC （n = 56）、发作性睡伴猝发性NwC （n = 27）、特发性嗜睡症IH （n = 11）、继发性发作性睡症（n = 3）和未明确的嗜睡症uneds （n = 17）。50例无白天嗜睡的神经系统患者作为对照。测量和结果：嗜睡组脑脊液HA水平（NC组中位数为708.62 pM，极值范围为[55.92-3335.50]；NwC组为781.34 [174.08- 431.50]；IH组为489.42 [177.45-906.70]，uned组为1155.40[134.80-2736.59]）或t-MHA水平无差异。脑脊液HA、t-MHA或HA + t-MHA与嗜睡、治疗摄入量和猝倒频率之间没有关联。年龄与血凝素水平呈轻微负相关。进一步调整年龄显示嗜睡症患者和对照组之间HA水平无显著差异。结论：脑脊液组胺和远端甲基组胺在发作性睡猝厥和其他病因的非下丘脑分泌素-1缺乏性中枢性嗜睡患者之间无显著差异；因此，这些测量对于评估中枢介导性嗜睡的病因或严重程度是没有用处的。
Study Objectives: To determine the activity of cerebral histaminergic system evaluated by CSF levels of histamine (HA) and tele-methylhistamine (t-MHA), its major metabolite, and their relationships with hypocretin-1 levels in a large population of patients with hypersomnia and neurological conditions.Design: A sensitive liquid chromatographic-electrospray/tandem mass spectrometric assay was developed for the simultaneous quantification of CSF HA and t-MHA.Setting: Data were collected and CSF hypocretin-1 levels were measured using radioimmunoassay at the Sleep Disorders Center, Montpellier, France. CSF HA and t-MHA were measured in Bioprojet-Biotech, FranceParticipants: One hundred fourteen unrelated patients with a suspicion of central hypersomnia underwent one night of polysomnography followed by the multiple sleep latency test. Sleep disorders were diagnosed clinically and using sleep studies: narcolepsy-cataplexy NC (n = 56), narcolepsy without cataplexy NwC (n = 27), idiopathic hypersomnia IH (n = 11), secondary narcolepsy (n = 3), and unspecified hypersomnia Uns EDS (n = 17). Fifty neurological patients without daytime sleepiness were included as controls.Measurements and Results: No between-hypersomnia group differences were found for CSF HA levels (median 708.62 pM extreme range [55.92-3335.50] in NC; 781.34 [174.08-4391.50] in NwC; 489.42 [177.45-906.70] in IH, and 1155.40 [134.80-2736.59] in Uns EDS) or for t-MHA levels. No association was found between CSF HA, t-MHA, or HA + t-MHA, sleepiness, treatment intake, and frequency of cataplexy. A slight negative correlation was found between age and HA levels. Further adjustment for the age revealed no significant HA levels difference between hypersomnia patients and controls.Conclusion: CSF histamine and tele-methylhistamine did not significantly differ between patients with narcolepsy-cataplexy and other etiologies of non-hypocretin-1 deficient central hypersomnias; these measurements, therefore, are not useful in assessing the etiology or severity of centrally mediated hypersomnia.